DNA + Roche Deal Review with Mike King

BioBusiness.TV, the podcast! ver2

You are Watching: Roche and Genentech, Deal Review, with Mike King. Mike King and Daniel Teper discuss the Genentech / Roche deal. Genentech’s Board of Directors say $89 per share is inadequate, Roche’s management feels it is more than generous. Genentech shareholders like this stock, and are reluctant to sell for less than $120-135. Why does Roche want the remaining 56% of Genentech? Will Roche be able to retain the innovation that made Genentech so successful? What are the odds of this deal closing? This interview was conducted at the NASDAQ Marketsite, on August 13th, 2008, in New York City. Featuring: * Michael King, Director of Research, Rodman & Renshaw * Daniel Teper, Managing Partner of Bionest Partners, and Founder & Chairman of BioBusiness.TV DISCLAIMER: BIOBUSINESS.TV IS AN INDEPENDENT MEDIA, AND A PLATFORM FOR THE EXCHANGE OF IDEAS AND OPINIONS. BIOBUSINESS.TV STRIVES TO ENHANCE THE QUALITY AND ACCESSIBILITY OF INDUSTRY DATA, AND TO DELIVER INFORMATION THAT INVESTORS AND EXECUTIVES CAN RELY UPON TO MAKE SOUND, INFORMED FINANCIAL AND MANAGERIAL DECISIONS. VIEWERS SHOULD VERIFY ALL CLAIMS AND DO THEIR OWN DUE DILIGENCE BEFORE INVESTING IN ANY SECURITIES MENTIONED. INVESTING IN SECURITIES IS SPECULATIVE AND CARRIES A HIGH DEGREE OF RISK.